EP-B1-Modif

lfoppiano · Sep 8, 2017 · ebfab21 · ebfab21
1 parent 85e5605
commit ebfab21
Showing 1 changed file with 2 additions and 2 deletions.
diff --git a/resources/dataset/quantities/corpus/xml/staging/EP-0505058-B1.tei.xml b/resources/dataset/quantities/corpus/xml/staging/EP-0505058-B1.tei.xml
@@ -319,7 +319,7 @@ wherein Z has the same significance as described above, preferably in the presen
 			<figure><table cols="3"><row><cell>Compound No. </cell><cell>Concentration (µM) </cell><cell>Inhibition Rate (%) </cell></row><row><cell>1</cell><cell>100</cell><cell>-1 </cell></row><row><cell>2</cell><cell>100</cell><cell>51 </cell></row><row><cell>3</cell><cell>10</cell><cell>141 </cell></row><row><cell>4</cell><cell>10</cell><cell>58 </cell></row><row><cell>5</cell><cell>10</cell><cell>53 </cell></row><row><cell>6</cell><cell>10</cell><cell>38 </cell></row><row><cell>7</cell><cell>10</cell><cell>32 </cell></row><row><cell>8</cell><cell>10</cell><cell>18 </cell></row></table></figure>
 		</p>
 		<head xml:id="_b1c62">Test Example 3 Acute toxicity test</head>
-		<p xml:id="_b7e8b">A test compound was orally administered to three dd-strain male mice weighing <measure type="interval"><num type="base">20</num> ± <num type="range">1</num> <measure type="MASS" unit="g">g</measure></measure>. The minimum lethal dose (MLD) was determined by observing the mortality for <measure type="value"><num>7</num> <measure type="TIME" unit="day">days</measure></measure> after the administration. </p><p xml:id="_d10b5">The results are shown in Table 5.
+		<p xml:id="_b7e8b">A test compound was orally administered to <measure type="value"><num>three</num> dd-strain male mice weighing <measure type="interval"><num type="base">20</num> ± <num type="range">1</num> <measure type="MASS" unit="g">g</measure></measure>. The minimum lethal dose (MLD) was determined by observing the mortality for <measure type="value"><num>7</num> <measure type="TIME" unit="day">days</measure></measure> after the administration. </p><p xml:id="_d10b5">The results are shown in Table 5.
 			<figure><table cols="2"><row><cell>Compound No. </cell><cell>MLD (mg/kg) </cell></row><row><cell>4</cell><cell>&gt; 300 </cell></row><row><cell>7</cell><cell>&gt; 300 </cell></row></table></figure>
 		</p>
 		<p xml:id="_37c9c">Compound (I) or a pharmaceutically acceptable salt thereof may be used as it is, or in various pharmaceutical forms. The pharmaceutical composition of the present invention can be prepared by uniformly mixing an effective amount of Compound (I) or a pharmaceutically acceptable salt thereof as the active ingredient with pharmaceutically acceptable carriers. The pharmaceutical compositions are desirably in a single dose unit suited for oral or parenteral administration. </p>
@@ -329,7 +329,7 @@ wherein Z has the same significance as described above, preferably in the presen
 		<p xml:id="_25607">The present invention is described by referring to Examples and Reference Examples below. </p> 
 		<head xml:id="_8b59b">Example 1 </head>
 		<head xml:id="_d3407">4,5-Dihydro-7-hydroxy-5-oxo-N-(3-pyridyl)thieno[3,2-b]pyridine-6-carboxamide (Compound 1)</head>
-		<p xml:id="_72938">A mixture of <measure type="value"><num>2.43</num> <measure type="MASS" unit="g">g</measure></measure> (<measure type="value"><num>10.2</num> <measure type="AMOUNT_OF_SUBSTANCE" unit="mmol">mmols</measure></measure>) of ethyl 4,5-dihydro-7-hydroxy-5-oxothieno[3,2-b]pyridine-6-carboxylate [J. Chem. Res. (S), 6 (1980); J. Chem. Res. (M), 113 (1980)], <measure type="value"><num>1.00</num> <measure type="MASS">g</measure></measure> (<measure type="value"><num>10.6</num> <measure type="AMOUNT_OF_SUBSTANCE" unit="mmol">mmols</measure></measure>) of 3-aminopyridine, <measure type="value"><num>50</num> <measure type="VOLUME" unit="ml">ml</measure></measure> of xylene and <measure type="value"><num>10</num> <measure type="VOLUME">ml</measure></measure> of dimethylformamide was heated at <measure type="value"><num>140</num><measure type="TEMPERATURE" unit="°C">°C</measure></measure> for <measure type="value"><num value="1">an</num> <measure type="TIME" unit="h">hour</measure></measure>. After completion of the reaction, insoluble matters were filtered and recrystallized from dimethylformamide to give <measure type="value"><num>1.56</num> <measure type="MASS">g</measure></measure> (yield: <measure type="value"><num>54</num><measure type="FRACTION" unit="%">%</measure></measure>) of Compound 1.
+		<p xml:id="_72938">A mixture of <measure type="value"><num>2.43</num> <measure type="MASS" unit="g">g</measure></measure> (<measure type="value"><num>10.2</num> <measure type="AMOUNT_OF_SUBSTANCE" unit="mmol">mmols</measure></measure>) of ethyl 4,5-dihydro-7-hydroxy-5-oxothieno[3,2-b]pyridine-6-carboxylate [J. Chem. Res. (S), 6 (1980); J. Chem. Res. (M), 113 (1980)], <measure type="value"><num>1.00</num> <measure type="MASS">g</measure></measure> (<measure type="value"><num>10.6</num> <measure type="AMOUNT_OF_SUBSTANCE" unit="mmol">mmols</measure></measure>) of <measure type="value"><num>3</num>-aminopyridine, <measure type="value"><num>50</num> <measure type="VOLUME" unit="ml">ml</measure></measure> of xylene and <measure type="value"><num>10</num> <measure type="VOLUME">ml</measure></measure> of dimethylformamide was heated at <measure type="value"><num>140</num><measure type="TEMPERATURE" unit="°C">°C</measure></measure> for <measure type="value"><num value="1">an</num> <measure type="TIME" unit="h">hour</measure></measure>. After completion of the reaction, insoluble matters were filtered and recrystallized from dimethylformamide to give <measure type="value"><num>1.56</num> <measure type="MASS">g</measure></measure> (yield: <measure type="value"><num>54</num><measure type="FRACTION" unit="%">%</measure></measure>) of Compound 1.
 			<figure><table cols="4"><row><cell>Elemental analysis: C13H9N3O3S </cell></row><row><cell>Calcd. (%) :</cell><cell>C 54.35,</cell><cell>H 3.16,</cell><cell>N 14.63 </cell></row><row><cell>Found (%) :</cell><cell>C 54.11,</cell><cell>H 2.85,</cell><cell>N 14.48 </cell></row></table></figure>
 IR (KBr) <measure type="list"><measure type="ENERGY" unit="cm^-1">cm-1</measure>:<num>3450</num>(br), <num>1638</num>, <num>1594</num>, <num>1547</num>, <num>1480</num>, <num>1408</num>, <num>1364</num>, <num>1264</num>, <num>1228</num>, <num>799</num>, <num>761</num></measure> 
 NMR (CF3 CO2 D) δ <measure type="list">(<measure type="CONCENTRATION" unit="ppm">ppm</measure>):<num>9.79</num>(1H, s), <num>8.81</num>(1H, d, J= <measure type="value"><num>8.8</num><measure type="FREQUENCY" unit="Hz">Hz</measure></measure>), <num>8.63</num>(1H, d, J=<measure type="value"><num>5.1</num><measure type="FREQUENCY" unit="Hz">Hz</measure></measure>), <num>8.15</num>(1H, m), <num>8.10</num> (1H, d, J=<measure type="value"><num>5.4</num><measure type="FREQUENCY" unit="Hz">Hz</measure></measure>), <num>7.28</num>(1H, d, J=<measure type="value"><num>5.4</num><measure type="FREQUENCY" unit="Hz">Hz</measure></measure>)</measure></p>